Brief: Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01

Oculis Holding AG

20/12/2023 11:44

Dec 20 (Reuters) - Oculis Holding AG  CR5.F :
    * OCULIS ANNOUNCES FIRST PATIENT FIRST VISIT IN PHASE 3
OPTIMIZE-2
TRIAL OF OCS-01 FOR THE TREATMENT OF INFLAMMATION AND PAIN
FOLLOWING CATARACT SURGERY
    * OCULIS HOLDING AG - OPTIMIZE-2 TOPLINE READOUT EXPECTED
BEFORE
END OF 2024 TO SUPPORT NDA SUBMISSION

Source text for Eikon:  ID:nGNX3zrZdj 
Further company coverage:  CR5.F 

 ((Reuters.Briefs@thomsonreuters.com;))